Bayer Aktiengesellschaft

Bayer Pharma Aktiengesellschaft

Bayer Intellectual Property Gmbh

Michael Sperzel

Karl-Heinz Schlemmer

Susanne Röhrig

Mazen Es-Sayed

Graham Sturton

Rolf Henning

Ulrich Nielsch

Joachim Schuhmacher

Hans-Georg Lerchen

Johannes Köbberling

Mary F Fitzgerald

Nils Burkhardt

Christian Stegmann

Karsten Von Dem Bruch

Manuel Ellermann

Tom Kinzel

Maria Köllnberger

Kristin Beyer

Matthias Werner

Gabriele Br&auml;unlich

R&uuml;diger Fischer

Jorma Haßfeld

Martin Bechem

Carsten Schmeck

Klemens Lustig

Christoph Gerdes

Stefan Heitmeier

Mark Jean Gnoth

Yolanda Cancho Grande

Andreas Wilmen

Dmitry Zubov

Trevor S Abram

Niels Svenstrup

Ulrich Rester

Stephan Siegel

Burkhard Fugmann

J&ouml;rg Baumgarten

Klaus G Stunkel

Jorg Baumgarten

Stephan Schneider

Helmut Brunner

Stephen Richard Tudhope

Yolanda Cancho-Grande

Rudiger Fischer

Arnel B Concepcion

Jochen Strayle

Barbara Briggs

Norbert Piel

Uwe Petersen

Lutz Heuer

Peter Wachtler

Oswald Lockhoff

William H Bullock

John W Goossens

Klaus Dieter Bremm

Michael Lögers

Horst-Peter Antonicek

J&uuml;rgen Stoltefuss

Jorma Haβfeld

Susanne Rohrig

Jürgen Stoltefuss

Michael L&ouml;gers

Gabriele Braunlich

Jorma Hassfeld

Walter Weichel

Werner Stürmer

Jan Stampfuß

Heinz Hildebrand

Inge Flesch

Burkhardt Fugmann

Gabriele Br{umlaut Over (a)}unlich

Gabriele Bräunlich

Gaelle Valot

Imke Meyer

Werner St&uuml;rmer

Jörg Heiermann

Willem Jan Hengeveld

J&ouml;rg Buamgarten

Maria Kollnberger

Johannes Kobberling

Jochen Stayle

The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

(Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use

The present application relates to novel substituted piperidinylpyrazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired hemostatic disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of heavy menstrual bleeding, postpartum hemorrhage, hemorrhagic shock, hemorrhagic cystitis, gastrointestinal hemorrhage, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

Piperidinylpyrazolopyrimidinones and their use

The invention relates to substituted imidazo- and triazolopyrimidines and processes for their preparation, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, in particular of haematological disorders, preferably of leucopenias and neutropenias.

Substituted imidazopyrimidines and triazolopyrimidines

The present invention relates to 6-carboxyphenyldihydropyridazinone derivatives having the formulawherein R, R, R, A, D, G, and E are as defined in the specification and claims, a process for preparing these materials, pharmaceutical compositions containing them, and a method for using them in the treatment of anemias.

6-carboxyphenyldihydropyridazinone derivatives and use thereof

Tetrahydroquinolinyl 6-methyldihydrothiadiazinone derivatives and use thereof

N-(3-benzofuranyl)urea-derivatives are prepared by reacting of 3-amino-substituted benzofuranes with appropriate substituted isocyanates or isothiocyanates. The N(3-benzofuranyl)urea-derivatives can be used as active ingredients in medicaments particularly for the treatment of acute and chronic inflammatory processes.

N-(3-benzofuranyl)urea-derivatives

Benzofuranylsulfonates

The present invention relates to glycoconjugates of 20(S)-camptothecin, in which a 3-O-methylated &bgr;-L-fucose unit is linked to the 20-hydroxyl group of a camptothecin derivative via a thiourea-modified peptide spacer. The invention furthermore relates to processes for the preparation of the compounds according to the invention and to their use as medicaments, in particular in connection with oncoses.

20(S) camptothecin glycoconjugates

The present invention relates to glycoconjugates of camptothecin derivatives in which at least one carbohydrate component is linked via suitable spacers with the 20-hydroxyl group of a camptothecin derivative. The invention furthermore relates to processes for preparing the compounds according to the invention and to their use as medicaments, in particular in connection with cancer.

Glycoconjugates from modified camptothecin derivatives (20-O-linkage)

N-(3-benzofuranyl) urea-derivatives

The invention relates to cytostatics which, by modification with sugar, are tumor-specific. Suitable spacers ensure serum stability and at the same time an intracellular action.

Sugar-modified cytostatics

3-Urea-pyridofurans and -pyridothiophenes are prepared by reacting appropriately substituted 3-amino-pyridofurans or -pyridothiophenes with isocyanates or isothiocyanates. The 3-urea-pyridofurans and -pyridothiophenes can be used as active ingredients in medicaments, particularly in medicaments for the treatment of acute and chronic inflammatory processes.

3-Ureido-pyridofurans and -pyridothiophenes for the treatment of inflammatory processes

Growing community of inventors

Wuppertal, Germany

Michael Sperzel